UK-based AI precision medicine PrecisionLife has identified 59 drugs that could be repurposed to improve the survival rate of severe Covid-19 patients who develop life-threatening sepsis.
These drugs were found by mining the UK Biobank to find sepsis risk genes and establish how many present in severe Covid-19 patients; PrecisionLife found 70 sepsis genes, with 61% of them presenting in Covid-19 patients and 13 of those having known druggable targets.
The company’s CEO Dr Steve Gardner explained: “Our high-resolution genomic analysis tools have allowed us to develop new insights into two serious and complex diseases for which new therapeutic options are urgently required.
“We hope that these will lead to better understanding of what drives sepsis in COVID-19 patients and result in new ways to treat seriously ill patients.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData